Combination of two beta-glucans reduced inflammatory biomarkers in COVID-19 patients – India clinical trial 02-Feb-2022 By Guan Yu Lim The combination of two beta-glucans produced by Aureobasidium Pullulans (AFO-202 and N-163) strains along with standard treatment was shown to reduce inflammatory biomarkers in COVID-19 patients, compared to just the standard treatment alone.